Latest News

 Filter by Provider

The daily Elliott Wave setup for Walmart suggests the formation of wave (iii) is underway.

After opening on a lower note, Indian benchmark indices pared some gains as the session progressed, ending the day marginally lower.

JetBlue CEO Joanna Geraghty confirmed the alliance will not lead to a merger, citing caution after years of scrutiny from the Department of Justice.

Many Americans fear Social Security will disappear by the time they retire, creating an urgent need for personal saving.

Sanofi will pay $129 per share in cash at closing, representing a 27% premium to Blueprint’s closing price on Friday of $101.35.

UBER TECHNOLOGIES INC (NYSE:UBER) offers strong growth potential with reasonable valuation, solid financial health, and improving profitability, making it a candidate for growth investors.

The USD/JPY pair fell to 143.58, marking its third consecutive day of losses. The Japanese yen continues to gain ground as demand for safe-haven assets rises amid escalating global trade tensions.

Microsoft Corporation (NASDAQ: MSFT) has announced a $400 million investment in Switzerland to bolster its cloud computing and artificial intelligence (AI) infrastructure.

"Consumers are cooking at home at the highest levels since early 2020," Campbell's CEO Mick Beekhuizen says.

Hyperscale Data sells minority stake for $4.65M, aligning with strategy to divest non-core investments. Focus now on 617K sq ft data center for AI.

April's PCE shows that disinflation has set in, making it complicated for the Federal Reserve to hold rates amid tariff turmoil.

JPMorgan strategist Mislav Matejka warned that the current tariff landscape is more severe than many had anticipated earlier in the year.

Transportadora de Gas del Sur SA (NYSE:TGS) meets key CANSLIM criteria with strong earnings growth, high relative strength, and solid fundamentals. A potential candidate for growth investors.

So far this year, the U.S. stock market has experienced a bear market, followed by a recovery.

Boeing stock upgraded to buy as Dow Jones jet maker plays a key role in Trump trade deals. BA stock rallies 63% from April low.

Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved efficacy and safety profile.

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.

SEA LTD (NYSE:SE) is a high-growth stock with strong fundamentals and a bullish technical setup, making it a candidate for investors seeking growth opportunities.

We expect a limited weakening of the zloty and flattening of the yield curve, with lower odds of cuts and higher sovereign risk premium.

Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.

Lyra's LYR-210 met key goals in a Phase 3 trial for chronic rhinosinusitis, showing early and sustained symptom relief with a favorable safety profile.

Cathie Wood sold Tesla stock repeatedly in last week's stock market.

Southwest Airlines to launch first trans-Pacific partnership with China Airlines, expanding global connectivity and customer access by 2026

Here's what fundamental and technical analysis says about Google stock as generative AI presents new opportunities and risks.

AXON ENTERPRISE INC (NASDAQ:AXON) shows strong growth fundamentals and bullish technical trends, making it a stock worth watching for investors seeking growth opportunities.

2025 has certainly kept us on our toes. After falling by 21% in March and April, spreading panic among investors who feared an all-out economic war with China, the S&P 500 staged an impressive rally.

President Donald Trump claimed losing legal challenges to his sweeping tariffs would lead to the "economic ruination" of America after federal courts blocked his emergency trade powers while an appeals court provided temporary relief.

Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.

Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neutral.